Search for: "Morris v. Merck "
Results 1 - 20
of 27
Sorted by Relevance
|
Sort by Date
20 Jun 2014, 8:25 am
Merck & Co., 195 N.J. 51, 948 A.2d 587 (2008). [read post]
20 Feb 2007, 7:00 am
"The decision is Philip Morris USA v. [read post]
2 Jul 2009, 5:18 am
Philip Morris, Inc., ___ P.3d ___, 2009 WL 1563373 (Nev. [read post]
4 Jan 2011, 2:45 pm
Papadopoulos v. [read post]
30 Jul 2008, 10:26 am
Merck & Co., 195 N.J. 51, 948 A.2d 587 (2008). [read post]
5 Sep 2007, 7:39 am
Merck sought review in the Fifth Circuit, which directed the district court to adopt Merck's proposed procedure under which Merck would identify 2,000 documents for further examination and then provide additional support and input for the claims as necessary. [read post]
2 Aug 2011, 9:25 am
KSR v. [read post]
25 Jan 2010, 5:00 am
Philip Morris Inc., 11 Cal. [read post]
15 Jun 2012, 2:08 pm
Merck & Co., 2006 U.S. [read post]
15 Apr 2011, 6:02 am
Morris v. [read post]
27 Aug 2010, 2:41 pm
Philip Morris USA, Inc., 837 A.2d 534, 541 (Pa. [read post]
23 Dec 2020, 5:31 am
In IPCom v HTC [2020] EWHC 2941 (Pat), IPCom sought to plead a similar point but Birss J took a harder line. [read post]
21 Jun 2013, 6:43 pm
Philip Morris USA, Inc., 449 F. [read post]
7 Nov 2014, 5:52 am
Ellis v. [read post]
15 Apr 2009, 4:44 am
Philip Morris Inc., 964 F. [read post]
24 May 2007, 10:40 am
George v. [read post]
21 Feb 2019, 4:00 am
Court of Appeal’s ruling in R. v. [read post]
11 Feb 2011, 7:51 am
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
30 May 2012, 1:37 pm
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
22 Jun 2011, 7:09 am
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
